Disease Markers

Disease Markers / 2013 / Article

Clinical Study | Open Access

Volume 35 |Article ID 932356 | 8 pages | https://doi.org/10.1155/2013/932356

Association of a FGFR-4 Gene Polymorphism with Bronchopulmonary Dysplasia and Neonatal Respiratory Distress

Academic Editor: Ross Molinaro
Received01 May 2013
Accepted01 Oct 2013
Published31 Oct 2013

Abstract

Background. Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease of premature birth, characterized by impaired alveolar development and inflammation. Pathomechanisms contributing to BPD are poorly understood. However, it is assumed that genetic factors predispose to BPD and other pulmonary diseases of preterm neonates, such as neonatal respiratory distress syndrome (RDS). For association studies, genes upregulated during alveolarization are major candidates for genetic analysis, for example, matrix metalloproteinases (MMPs) and fibroblast growth factors (FGFs) and their receptors (FGFR). Objective. Determining genetic risk variants in a Caucasian population of premature neonates with BPD and RDS. Methods. We genotyped 27 polymorphisms within 14 candidate genes via restriction fragment length polymorphism (RFLP): MMP-1, -2, -9, and -12, -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, Signal-Regulatory Protein α (SIRPA) and Thyroid Transcription Factor-1 (TTF-1). Results. Five single nucleotide polymorphisms (SNPs) in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 are associated ( ) with RDS, defined as surfactant application within the first 24 hours after birth. One of them, in FGFR-4 (rs1966265), is associated with both RDS ( ) and BPD ( ). Conclusion. rs1966265 in FGF receptor 4 is a possible genetic key variant in alveolar diseases of preterm newborns.

1. Introduction

Great progress has been made in neonatal care over the last few decades, reflected by improving survival rates and clinical outcomes of preterm infants. Despite these advances, 45 years after its first description [1], bronchopulmonary dysplasia (BPD) remains a major complication of premature birth, causing ongoing morbidity and mortality: it is the most common neonatal chronic lung disease, affecting around 25% to 35% of VLBW neonates (very low birth weight, <1500 g) [2], and is associated with increased risk for rehospitalization [3, 4], cognitive delay, and neurosensory deficits [5].

Initially described by Northway et al. in 1967, the “old BPD” mainly affected modestly premature newborns suffering from respiratory distress and therefore mechanically ventilated with high levels of supplemental oxygen [1]. With the introduction of surfactant treatment, prenatal maternal use of glucocorticoids, improved nutrition, and ventilator strategies the clinical course and pathology of BPD have changed considerably. Unlike the original description, today’s “new BPD” is mainly regarded as a disruption of distal lung growth [6, 7]. The underlying etiology is multifactorial. Thus, influenced by both genetic susceptibility [8, 9] and environmental factors [7] on the immature lung, the pathophysiology is characterized by inflammation, abnormal microvascularization, and impaired alveolarization [10].

Alveolar formation of the primitive saccules is a complex process of epithelial morphogenesis, capillary growth, and coordinated extracellular matrix (ECM) remodelling. At this, fibroblast growth factor (FGF) signalling and matrix metalloproteinase (MMP) activity play eminent roles.

MMPs are zinc-dependent proteolytic enzymes degrading all forms of ECM-components [11]. Some MMPs are upregulated in inflammatory environment and yet are involved in pulmonary host defense [11]. There is evidence for some MMP isoforms being important determinants for alveolarization, especially MMP-2 [12], -9 [13], and -16 [14]: MMP-2 deficient mice showed fewer and larger alveoli with thinner interstitial tissue [12]. Hadchouel et al. demonstrated an increase of MMP-16 activity during the alveolar stage and moreover found two SNPs within the MMP-16 gene being associated with lower tracheal MMP-2 and -16 activity and to protect from BPD [14]. Prospecting further potential biomarkers for BPD, also MMP-9 shows some promise; for example, Harijith et al. highlighted a MMP-9-dependent lung injury pathway in an IFN -mediated animal model of BPD. Mice with a partial MMP-9 deficiency showed a reversal of IFN -induced lung injury during hyperoxia [13].

MMPs, particularly MMP-2 and -9, activate fibroblast growth factors (FGFs) by cleavage in the ECM, especially during angiogenesis [15]. In turn activated FGFs upregulate MMP expression [15]. FGFs are secreted glycoproteins involved in interactions between epithelium and mesenchyme regulating cell migration and proliferation in embryonic development, especially in fetal pulmogenesis [16, 17]. Their signalling depends on membrane-located receptors (FGFRs) with a tyrosine kinase domain, encoded by four different genes (FGFR 1–4) [1820]. They are all translated in developing lungs and are suggested to play major roles in modifying distal lung patterns during alveolarization [21]; for example, FGFR-3-FGFR-4 double-knockout mice show no alveolarization [22].

It has been assumed that heritable determinants contribute significantly to both BPD [8, 23] and RDS [24]. On this account, we were interested in identifying genetic risk factors in a Caucasian population of premature newborn with BPD and RDS. We genotyped 27 polymorphisms within fourteen candidate genes for BPD: MMP-1, -2, -9, -12, and -16, FGF receptors 2 and 4, FGF-2, -3, -4, -7, and -18, signal-regulatory protein α (SIRPA), and thyroid transcription factor-1 (TTF-1). We also included SIRPA because of the known effect on surfactant proteins [25] and inhibition of macrophages [26], as well as TTF-1 due to its effect on lung differentiation [27].

2. Material and Methods

2.1. Subjects

We recruited preterm neonates (≤28 weeks of gestation) born between January 1996 and September 2010 at the Centre for Pediatrics and Adolescent Medicine, University Hospital Freiburg, Germany. To provide an ethnically homogenous population, all infants were of Caucasian origin. Twins and siblings were excluded from the study as were children with chromosomal aberrations, congenital heart defects, or other major congenital malformations. DNA was collected by buccal swabs or by routine blood sampling, between 2 weeks up to 2 years of age.

Medical charts of all recruited infants were reviewed and clinical data were recorded. This included gestational week, number of days with supplemental oxygen, need of mechanical ventilation and positive airway pressure, and need of surfactant therapy. As described previously [28], the subdivision of our BPD study population was based on the analysis by Lavoie et al. about the heritability of BPD [9] according to the consensus defined by the National Institute of Health [6]: the BPD population included all infants with moderate and severe BPD, that is, supplemental oxygen for at least 28 days plus need of oxygen and/or positive pressure at 36 weeks of gestation, whereas the control population consisted of all preterm neonates with no or mild BPD.

Recruiting neonates for the RDS population was targeted on severe cases of respiratory distress by including only newborns depending on surfactant within the first 24 hours after birth (see Supplementary Material available online at http://dx.doi.org/10.1155/2013/932356). At our Neonatal Intensive Care Unit (NICU) the following approach has been applied regarding the treatment with surfactant: avoiding of intubation independent of the gestational week. Therefore, even very premature infants are only intubated if they show failure of ventilation and/or need of supplemental oxygen above 40%. Once they required intubation during the immediate postnatal period, they receive surfactant within 2 hours. This practice was consistent during the whole study period.

2.2. Genotyping

DNA was extracted by standard procedures as previously described [28]. Genotyping was carried out by RFLP following polymerase chain reaction amplification (PCR). Studied SNPs are summarized in Table 1. We included a minority of polymorphisms that already had been tested for other pathologies (rs1799750 in MMP1 [29] and rs2276109 and rs652438 in MMP12 [30]).


GenePolymorphismAllelesGene region

MMP-1 rs1799750G/GGPromotor
rs7125062C/TIntron

MMP-2 rs7201A/C3′UTR
rs243865C/TPromotor
rs17301608C/TIntron

MMP-9 rs20544C/T3′UTR
rs3918242C/TPromoter
rs17576A/G279 Gln/Arg

MMP-12 rs2276109A/GPromoter
rs652438A/G357 Asn/Ser

MMP-16 rs2664352C/TIntron

FGFR-2 rs2981579A/GIntron
rs1219648A/GIntron

FGFR-4 rs376618A/G136 Leu/Pro
rs1966265A/G10 Ile/Val

FGF-2 rs11938826C/GIntron

FGF-3 rs11263591G/CIntron
rs10796856T/CIntron

FGF-4 rs3740639 C/T3′UTR

FGF-7 rs16962440C/TIntron

FGF-7, C15 or f33 rs4316697 G/AIntron
rs10519230C/GIntron

FGF-18 rs4559013G/AIntron

SIRPA rs3828016A/GIntron
rs4814734A/TIntron

TTF-1 rs11628131A/CPromoter
rs999460C/TDownstream

For PCR reactions, genomic DNA was initially denatured at 94°C for 5 minutes and underwent 35–40 cycles of denaturation (94°C for 30 seconds), annealing (1 minute, corresponding temperatures displayed in Table 2), extension reaction (72°C for 1 minute), and a final extension step at 72°C for 8 minutes. In Table 2 primers, annealing temperatures, and restriction enzymes (RE) are shown. Some primers contain intended single nucleotide mismatches (mutagenic primers) to create sites for restriction enzymes.


GenePolymorphismForward-primerReverse-primerPCR RE

MMP-1 rs71250625′-ATC TCT GTC GGC AAA TTC GT-3′5′-AGC AAC AAG AAG GAG CTG GA-3′56.5°C, 35 cycl.BseG1

MMP-2 rs72015′-TGC CCA AGA ATA GAT GCT GA-3′5′-CTG TGA GCC ACA GAA GGT TG-3′59.1°C, 35 cycl.MboI
rs2438655′-CTG ACC CCC AGT CCT ATC TG-3′5′-GAG CTG AGA CCT GAA GAG CCA AA-3′59.1°C, 40 cycl.BstXI
rs173016085′-GCA GTG TAG ACA CTA GAG GAA GGA T-3′5′-GTC ACC AAG GCC TGT ACC AC-3′59.1°C, 40 cycl.DpnII

MMP-9 rs205445′-AGT GCC CTG AGG ACT AGA G-3′5′-CAT ACA TGC ATA CAT ACG TGC ATA C-3′54.2°C, 40 cycl.SacI
rs39182425′-GCC TGG CAC ATA GTA GGC CC-3′5′-CTT CCT AGC CAG CCG GCA TC-3′ 67°C, 40 cycl.XceI
rs175765′-AAT TCA CCC TCC CGC ACT CT-3′5′-GTT TTG GGG GCC AAT ACA TGA-3′56.5°C, 35 cycl.SmaI

MMP-16 rs26643525′-GGT AGG CCT GCT TTG GTT CT-3′5′-GCC TTC CAA ACT CCA CTC ACA T-3′56.5°C, 35 cycl.NlaIII

FGFR-2 rs29815795′-CCA CTC AAG TCC CTG CTT GT-3′5′-GTG GGG ACT GAT CAG AGG AA-3′56.5°C, 40 cycl.AccI
rs12196485′-GCA CGC CTA TTT TAC TTG ACA CGC-3′5′-CAT TGT GGT GAT CCT TCA CG-3′59.1°C, 40 cycl.HhaI

FGFR-4 rs3766185′-GGG GGT AAC TGT GCC TAT TCTA-3′5′-TAG CAG GGA GTG AAG GGA TG-3′56.5°C, 40 cycl.XbaI
rs19662655′-CAA AGG TGC ACG TGT AGC AG-3′5′-TCC CAC CTC AGA AGC CAT AC-3′56.5°C, 40 cycl.BamHI

FGF-2 rs119388265′-GAT GAT TTC TCA GGG CCA AA-3′5′-GCT TCA CAT GCC TAT TTG CTT-3′59.1°C, 40 cycl.AluI

FGF-3 rs112635915′-GGT GTG TGG GCT GAA GAG AT-3′5′-CAC CCT GAC ACT CCT GGT CT-3′61.8°C, 40 cycl.TaqI
rs107968565′-CTT CCC CTC CTA GGC TTC AG-3′5′-GAA TGC CAG GTT AGC AAA GG-3′59.1°C, 40 cycl. HhaI

FGF-4 rs3740639 5′-AAA AAC ACA CCC GCA GAA CT-3′5′-TGA AGG TCA CCC ACT TCC TC-3′59.1°C, 40 cycl.HinfI

FGF-7 rs169624405′-TGT CGA ACA CAG TGG TAC CTG-3′5′-GCA AAA GGA AGA TGA GAA AAG AT-3′56.5°C, 40 cycl.EcoRV

FGF-7, C15 or f33rs4316697 5′-TGG CTC TTT CCA GCA ATT AGA-3′5′-CCC TTT CTC TCC CAG GTT CT-3′59.1°C, 40 cycl.TaiI
rs105192305′-AAT GTG ACC GCA TAT TGG TG-3′5′-CAT TTT GGG AAC TGG GGT AA-3′56.5°C, 35 cycl.TaqI

FGF-18 rs45590135′-GAG GCA CAG AAT GAG GAA GG-3′5′-TAC CTG GGC TCT CAA CAT CC-3′56.5°C, 35 cycl.Alw26I

SIRPA rs38280165′-TCA AAC CCA GGC TTT CTG AC-3′5′-AAC CAA GGC TGG CAC ATA AG-3′ 63°C, 40 cycl.NlaIII
rs48147345′-CTG TGT ACA TCC TCT TAA ATG GAC-3′5′-TGC TGT GTG CCA GAG TAT GC-3′59.1°C, 40 cycl.HinfI

TTF-1 rs116281315′-TGC AGC CTC ATT CAG CTT TA-3′5′-GGT TGG AGA GGA GGA AAG GA-3′56.5°C, 40 cycl.TaqI
rs9994605′-ACC TGG GCG AGA AGT GAG TA-3′5′-AGA GAG GGG AGA AGG AAT GG-3′56.5°C, 40 cycl.SspI

2.3. Sequencing

Accuracy of the RFLP was confirmed by sequencing via dideoxy chain termination method [31], respectively, three controls (homozygous wildtype, heterozygous, and homozygous mutation) for each polymorphism using the Big Dye Terminator cycle sequencing kit on an ABI 310 sequencer (Applied Biosystems). The RFLP analyses included these control references.

2.4. Statistical Analysis

Genotyping data of our case-control populations were analysed by using Armitage’s trend test (ATT) for possible association with BPD and RDS as specified previously [28]. Moreover ATT was used to calculate Hardy Weinberg equilibrium (HWE) for each polymorphism.

2.5. Approval

The collection of blood/buccal swabs and the experimental procedures were approved by the Ethical Committee of the University of Freiburg. Parents were given written and verbal information about the study and a statement of informed consent was signed by the parents of all enrolled children.

3. Results

The results of the 27 studied polymorphisms (Table 1) for association with bronchopulmonary dysplasia and neonatal respiratory distress are specified in Table 3 (BPD) and Table 4 (RDS).


GenePolymorphismGenotypes
BPD
HWE
BPD
Genotypes
controls
HWE
controls
values for association

MMP-1 rs179975016, 25, 140,59034, 44, 390.0090.532
rs712506241, 15, 30,36474, 43, 110.2410.126

MMP-2 rs720121, 28, 91,00043, 64, 210.8600.747
rs24386535, 18, 60,17080, 35, 120.0130.675
rs1730160827, 25, 110,28051, 63, 210.8570.769

MMP-9 rs2054417, 19, 170,05327, 60, 370.8560.508
rs391824235, 12, 40,07776, 36, 41.0000.894
rs1757624, 18, 120,04257, 46, 220.0320.639

MMP-12 rs227610944, 13, 20,32886, 38, 20.5220.574
rs65243852, 8, 01,00010, 19, 10.5870.615

MMP-16 rs266435212, 31, 19 1,00040, 57, 350.1200.185

FGFR-2 rs298157921, 32, 100,79951, 58, 250.2810.858
rs121964819, 33, 120,80452, 61, 200.8540.215

FGFR-4 rs37661835, 23, 50,74484, 40, 100.1320.432
rs196626547, 15, 10,47379, 45, 91.0000.023

FGF-2 rs1193882648, 14, 11,00096, 38, 10.3050.557

FGF-3 rs1126359125, 22, 150,03745, 61, 290.3820.710
rs1079685617, 26, 220,13537, 59, 400.1250.632

FGF-4 rs3740639 33, 23, 70,36574, 46, 150.0860.815

FGF-7 rs1696244017, 35, 120,61442, 70, 250.7300.656

FGF-7, C15 or f33 rs4316697 28, 30, 40,37765, 55, 150.5500.868

FGF-7, C15 or f33 rs1051923037, 23, 31,00073, 50, 110.5170.421

FGF-18 rs455901322, 23, 170,04545, 62, 221.0000.387

SIRPA rs382801620, 31, 121,00048, 59, 270.2880.788
rs481473416, 37, 100,20646, 62, 250.5980.553

TTF-1 rs1162813120, 27, 160,31154, 50, 290.0120.287
rs99946034, 19, 110,01960, 51, 240.0400.414


GenePolymorphismGenotypes RDSHWE
RDS
Genotypes controlsHWE controls value for association

MMP-1 rs179975025, 44, 201,00024, 29, 330.0040.163
rs712506251, 36, 100.00366, 21, 90.3300.076

MMP-2 rs720130, 49, 160.67834, 43, 160.0670.648
rs24386558, 26, 110.01258, 27, 70.1390.540
rs1730160842, 47, 180,42237, 43, 140.8270.838

MMP-9 rs2054429, 34, 240,82814, 44, 300.0520.033
rs391824255, 23, 60,17857, 25, 21.0000.421
rs1757638, 30, 210,00545, 34, 130.1530.164

MMP-12 rs227610967, 27, 21,00064, 23, 11.0000.595
rs65243889, 10, 01,00073, 17, 11.0000.047

MMP-16 rs266435226, 46, 270,54626, 43, 270.3120.998

FGFR-2 rs298157933, 40, 200,84040, 52, 150.2890.351
rs121964842, 49, 160,83730, 47, 160.8330.347

FGFR-4 rs37661871, 27, 90,01851, 36, 61.0000.286
rs196626576, 28, 21,00050, 35, 80.6050.003

FGF-2 rs1193882680, 26, 10,69067, 26, 10.6840.586

FGF-3 rs1126359131, 48, 250,43840, 37, 190.0850.127
rs1079685633, 50, 260,44221, 38, 360.0920.036

FGF-4 rs3740639 57, 41, 71,00050, 30, 160.0090.209

FGF-7 rs1696244030, 57, 210,56630, 49, 170.8360.588

FGF-7 C15 or f33 rs4316697 56, 43, 71,00038, 44, 121.0000.044

FGF-7, C15 or f33 rs1051923061, 41, 50,79051, 33, 90.3010.418

FGF-18 rs455901332, 45, 260,23635, 43, 131.0000.079

SIRPA rs382801634, 53, 211,00037, 38, 190.1340.487
rs481473431, 58, 180,33432, 43, 170.6740.671

TTF-1 rs1162813136, 47, 230,32641, 30, 220.0020.453
rs99946056, 37, 160,02738, 36, 190.0820.121

3.1. Matrix Metalloproteinases

Among the 11 genotyped polymorphisms in different MMP genes (see Table 1) there was no BPD-associated polymorphism (Table 3) but two polymorphisms associated ( ) with RDS (rs20544 in MMP-9: ; rs652438 in MMP-12: , see Table 4). Both SNPs show no significant deviation from Hardy-Weinberg equilibrium, neither in the control nor in the case population. Analysis of rs20544 (C/T) identifies the T allele as protective against respiratory distress. For the genotyping results of the amino acid substitution rs652438 (A/G, Asn357Ser) the complete absence of the G/G homozygous genotype in the respiratory distress case population must be taken in account. The other MMP-SNPs showed no association, inclusively rs2664352 in MMP16, that had been associated with protection from BPD [14].

3.2. Fibroblast Growth Factor Receptors

The FGFR-4 SNP rs1966265, located in the exon region and causing an amino acid substitution of Isoleucine (Ile) for Valine (Val) is associated with both BPD ( ) and RDS ( ). Here the A/A genotype (Ile) could be identified as protective allele variant against our studied lung diseases. The association results from significant differences in allele frequencies: in both BPD and RDS analysis the G allele is more frequent in the disease populations (see Tables 3 and 4). The other SNPs in the FGFR genes showed no association with neither BPD nor respiratory distress.

3.3. Fibroblast Growth Factors

Whereas no association could be detected between the eight FGF-SNPs and BPD, rs10796856 in FGF-3 and rs4316697 in FGF-7 showed associations with RDS. Correspondent values are (rs10796856) and (rs4316697), and no deviations from Hardy-Weinberg equilibrium were detected (see Table 4).

3.4. SIRPA and TTF-1

The four SNPs in SIRPA and TTF-1 showed no association with neither BPD nor RDS. Analysis of TTF-1 rs999460 unfolds deviation from Hardy-Weinberg equilibrium in both case and one control populations in our Caucasian population (see Tables 3 and 4).

4. Discussion

Bronchopulmonary dysplasia and respiratory distress syndrome of preterm infants have complex pathogenic mechanisms. The aim of this study has been to identify genetic risk factors in an ethnically homogenous Caucasian population.

Genetic contribution to BPD is suggested on the basis of twin studies demonstrating that at least half of the susceptibility is hereditary [8, 9, 23]. Additionally, Lavoie et al. [9] could differentiate in their study that mild BPD (according to the National Institute of Child Health and Human Development consensus definition [6]) had been mainly attributable to shared environmental factors whereas moderate or severe BPD had been attributable to genetic influence. Following these findings, we defined our control population as neonates with no BPD or mild BPD, whereas our BPD population included neonates with moderate or severe BPD. Furthermore, we recruited only preterm neonates ≤28 weeks of gestational age for the BPD population to avoid false associations based on the fact that BPD hardly develops in newborn older than 30 weeks of gestational age.

In contrast to BPD, the results of twin studies on RDS susceptibility showed mostly contradictory results [24, 3235]. A twin study by Levit et al. with 332 twin pairs of a heterogeneous population has been the first one to include and assess the influence of several independent covariates, revealing that 50% of the variance to RDS susceptibility is hereditary [24].

Given these lines of evidence for genetic contribution, we have chosen the candidate-gene approach for our association study based on the hypothesis that genes fundamental in lung organogenesis and alveolar remodelling, that is, MMP and FGF, determine susceptibility to BPD and RDS.

Known genetic risk factors for RDS are mostly allelic polymorphisms of the genes encoding surfactant proteins SP-A1, SP-A2, and SP-B [36]. Anyhow, other determinants than components of the surfactant system might also affect the liability to RDS. Genes encoding for growth factors or enzymes that account for alveolarization through proper secondary septation and extracellular remodeling might affect the gas-exchange and therefore aggravate respiratory distress at birth.

Supposed genetic risk factors for BPD are mostly genes encoding components of innate immunity and antigen-presentation, cytokines, antioxidant defences, and angiogenic growth factors such as: mannose-binding lectin (MBL2) [37], tumor necrosis factor-alpha (TNF- ) [28, 38], human leucocyte antigen (HLA)-A, -B, and -C alleles [39], glutathione-S-transferase-P1 [40], and vascular endothelial growth factor (VEGF) [28]. Some years ago, two MMP-16 gene polymorphisms were demonstrated to protect from BPD and moreover to be associated with lower tracheal MMP-2 and -16 levels [14].

Matrix metalloproteinases are a family of zinc-dependent endopeptidases [11], and they degrade extracellular components and play a crucial role in lung development, especially during alveolarization. Particularly MMP-2 and -9 (so-called gelatinases A and B) seem to be relevant in extracellular remodeling and even pulmonary host defense. They degrade type IV collagen, fibronectin, elastin, and denatured collagen (gelatin). MMP-2 deficient mice show an abnormal saccular development with larger and simplified alveoles [12]. In line with this finding, newborns developing BPD showed low MMP-2 tracheal levels at birth [41, 42]. Recently, MMP-9 could be identified as a pathogenic key mediator in a murine model of BPD [13]. On the other hand, increased tracheal levels of MMP-9 early after birth have been associated with resolving RDS, suggesting that increase in MMP-9-activity is a physiologic repair response [43]. Dik et al. demonstrated that increased MMP-9 activity in neonatal lungs early after birth correlated with resolving respiratory distress syndrome, demonstrating a likely role of MMP-9 in pulmonary host defense [43].

In our study we identified an SNP (rs20544) in the MMP-9 gene to be associated ( ) with RDS, but not BPD. Respiratory distress syndrome has been defined as need of surfactant (see Supplementary Material). On one hand, ethnically homogenous populations like our Caucasian population are favourable to detect possible pathogenetic determinants, but one must bear in mind that the size of our RDS population is limited and the total numbers of neonates studied for each polymorphism vary slightly according to the recruiting time point. Furthermore, association studies on RDS are prone to confounding factors. Other pulmonary conditions such as a transient tachypnea provoked by wet lung syndrome or pulmonary infection might mimic respiratory distress syndrome caused by surfactant deficiency and thereby hamper the results of our study.

In our study, we included MMP-16 polymorphisms that had been associated with BPD in a French population (rs2664352) [14]. In our population rs2664352 did not show any association.

The FGF-3 polymorphism rs10796856 showed association with RDS ( ). Up to now, the role of FGF3 has been mainly studied in cancer diseases, that is, lung cancer [44], but its exact role in pulmogenesis remains elusive. FGF-3 is encoded by the fgf3/int2 gene. There is evidence for FGF-3 upregulation to be associated with alveolar type 2 cell hyperplasia [45] and downregulation to be associated with an excessive recruitment of free alveolar macrophages [45] which might lead to symptoms of respiratory distress. Furthermore it has been shown that FGF-3 stimulates the secretion of MMP-2 and -9 propeptides in vitro [46].

FGFR-4 polymorphism rs1966265 showed association with both respiratory distress ( ) and bronchopulmonary dysplasia ( ). The A/A genotype (encoding for Isoleucin instead of Valine) has been protective in our association study. The exact-test showed no deviation from Hardy Weinberg equilibrium for this SNP in both case and control populations, suggesting that the association does not result from population admixture or genotyping errors.

FGFR-1 to FGFR-4 are expressed in the lung and FGFR-3 and -4 signalling, in particular, appears to be fundamental in alveolar formation. Weinstein et al. demonstrated that mice deficient in both FGFR-3 and -4 show a completely blocked alveolarization and fail to show any formation of secondary septae, whereas solely FGFR-4(−/−) animals exhibit no significant abnormalities, revealing a cooperative effect of FGFR-3 and -4 in lung development [22]. Hyperoxia-exposed (FiO2 0.85) mice show a BPD-like lung pattern of enlarged airspaces and furthermore a reduced expression of FGFR-3 and -4, suggesting a pathogenic role in arrested lung development [47]. Srisuma et al. [48] replicated these results in FGFR-3 and -4 deficient mice and demonstrated in addition that FGFR-3/-4 signaling contributes to excessive elastin production and its alveolar accumulation, which is another typical feature of BPD. But these abnormalities have not been due to fibroblast defects but due to increased expression of paracrine factors of alveolar type 2 cell (AT2) [48].

If a reduction in FGFR-3 and -4 expression affects distal lung development, a functionally significant polymorphism within the correspondent gene possibly alters the susceptibility to alveolar disease such as BPD and RDS. Powell et al. showed that there is a peak of FGFR-4 expression at the day of birth, when respiratory distress syndrome occurs [21]. This supports the conclusion that defective FGFR-4 signalling possibly results in neonatal lung diseases.

Our associations do not justify general interpretation. False-positive results can only be excluded by replications in other study populations.

In conclusion, we describe five SNPs in MMP-9, MMP-12, FGFR-4, FGF-3, and FGF-7 that are associated ( ) in our Caucasian population with respiratory distress syndrome of the newborn, defined as surfactant application within the first 24 hours after birth. Among these polymorphisms one polymorphism in FGFR-4 (rs1966265) is additionally associated with bronchopulmonary dysplasia, demonstrating its possible role in the pathogenesis of newborn lung diseases on grounds of pulmonal immaturity.

The experiments with genetic material used from humans for this paper were undertaken with the understanding and written consent of each subject. The study conforms with The Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964).

Supplementary Materials

The supplementary material describes indications for surfactant treatment that are based on the European Consensus Statement.

  1. Supplementary Material

References

  1. W. H. Northway Jr., R. C. Rosan, and D. Y. Porter, “Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia,” The New England Journal of Medicine, vol. 276, no. 7, pp. 357–368, 1967. View at: Google Scholar
  2. M. C. Walsh, Q. Yao, P. Gettner et al., “Impact of a physiologic definition on bronchopulmonary dysplasia rates,” Pediatrics, vol. 114, no. 5, pp. 1305–1311, 2004. View at: Publisher Site | Google Scholar
  3. J. K. Chye and P. H. Gray, “Rehospitalization and growth of infants with bronchopulmonary dysplasia: a matched control study,” Journal of Paediatrics and Child Health, vol. 31, no. 2, pp. 105–111, 1995. View at: Google Scholar
  4. V. C. Smith, J. A. F. Zupancic, M. C. McCormick et al., “Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia,” Journal of Pediatrics, vol. 144, no. 6, pp. 799–803, 2004. View at: Publisher Site | Google Scholar
  5. B. Schmidt, E. V. Asztalos, R. S. Roberts et al., “Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms,” The Journal of the American Medical Association, vol. 289, no. 9, pp. 1124–1129, 2003. View at: Publisher Site | Google Scholar
  6. A. H. Jobe and E. Bancalari, “Bronchopulmonary dysplasia,” The American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 7, pp. 1723–1729, 2001. View at: Google Scholar
  7. J. P. Kinsella, A. Greenough, and S. H. Abman, “Bronchopulmonary dysplasia,” The Lancet, vol. 367, no. 9520, pp. 1421–1431, 2006. View at: Publisher Site | Google Scholar
  8. V. Bhandari, M. J. Bizzarro, A. Shetty et al., “Familial and genetic susceptibility to major neonatal morbidities in preterm twins,” Pediatrics, vol. 117, no. 6, pp. 1901–1906, 2006. View at: Publisher Site | Google Scholar
  9. P. M. Lavoie, C. Pham, and K. L. Jang, “Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health,” Pediatrics, vol. 122, no. 3, pp. 479–485, 2008. View at: Publisher Site | Google Scholar
  10. J. J. Coalson, “Pathology of new bronchopulmonary dysplasia,” Seminars in Neonatology, vol. 8, no. 1, pp. 73–81, 2003. View at: Publisher Site | Google Scholar
  11. K. J. Greenlee, Z. Werb, and F. Kheradmand, “Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted,” Physiological Reviews, vol. 87, no. 1, pp. 69–98, 2007. View at: Publisher Site | Google Scholar
  12. F. Kheradmand, K. Rishi, and Z. Werb, “Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2,” Journal of Cell Science, vol. 115, no. 4, pp. 839–848, 2002. View at: Google Scholar
  13. A. Harijith, R. Choo-Wing, S. Cataltepe et al., “A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia,” The American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 5, pp. 621–630, 2011. View at: Publisher Site | Google Scholar
  14. A. Hadchouel, F. Decobert, M. Franco-Montoya et al., “Matrix metalloproteinase gene polymorphisms and bronchopulmonary dysplasia: identification of MMP16 as a new player in lung development,” PLoS ONE, vol. 3, no. 9, Article ID e3188, 2008. View at: Publisher Site | Google Scholar
  15. P. R. Brauer, “MMPs—role in cardiovascular development and disease,” Frontiers in Bioscience, vol. 11, no. 1, pp. 447–478, 2006. View at: Publisher Site | Google Scholar
  16. J. M. Shannon and B. A. Hyatt, “Epithelial-mesenchymal interactions in the developing lung,” Annual Review of Physiology, vol. 66, pp. 625–645, 2004. View at: Publisher Site | Google Scholar
  17. K. Sekine, H. Ohuchi, M. Fujiwara et al., “Fgf10 is essential for limb and lung formation,” Nature Genetics, vol. 21, no. 1, pp. 138–141, 1999. View at: Publisher Site | Google Scholar
  18. C. A. Dionne, G. Crumley, F. Bellot et al., “Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors,” EMBO Journal, vol. 9, no. 9, pp. 2685–2692, 1990. View at: Google Scholar
  19. K. Keegan, D. E. Johnson, L. T. Williams, and M. J. Hayman, “Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 4, pp. 1095–1099, 1991. View at: Google Scholar
  20. J. Partanen, T. P. Mäkelä, E. Eerola et al., “FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern,” EMBO Journal, vol. 10, no. 6, pp. 1347–1354, 1991. View at: Google Scholar
  21. P. P. Powell, C. Wang, H. Horinouchi et al., “Differential expression of fibroblast growth factor receptors 1 to 4 and ligand genes in late fetal and early postnatal rat lung,” The American Journal of Respiratory Cell and Molecular Biology, vol. 19, no. 4, pp. 563–572, 1998. View at: Google Scholar
  22. M. Weinstein, X. Xu, K. Ohyama, and C. X. Deng, “FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung,” Development, vol. 125, no. 18, pp. 3615–3623, 1998. View at: Google Scholar
  23. R. A. Parker, D. P. Lindstrom, and R. B. Cotton, “Evidence from twin study implies possible genetic susceptibility to bronchopulmonary dysplasia,” Seminars in Perinatology, vol. 20, no. 3, pp. 206–209, 1996. View at: Google Scholar
  24. O. Levit, Y. Jiang, M. J. Bizzarro et al., “The genetic susceptibility to respiratory distress syndrome,” Pediatric Research, vol. 66, no. 6, pp. 693–697, 2009. View at: Publisher Site | Google Scholar
  25. S. J. Gardai, Y. Xiao, M. Dickinson et al., “By binding SIRPα or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation,” Cell, vol. 115, no. 1, pp. 13–23, 2003. View at: Publisher Site | Google Scholar
  26. K. Takenaka, T. K. Prasolava, J. C. Y. Wang et al., “Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells,” Nature Immunology, vol. 8, no. 12, pp. 1313–1323, 2007. View at: Publisher Site | Google Scholar
  27. V. Boggaram, “Thyroid transcription factor-I (TTF-I/Nkx2.I/TITFI) gene regulation in the lung,” Clinical Science, vol. 116, no. 1, pp. 27–35, 2009. View at: Publisher Site | Google Scholar
  28. B. Mailaparambil, M. Krueger, U. Heizmann, K. Schlegel, J. Heinze, and A. Heinzmann, “Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia,” Disease Markers, vol. 29, no. 1, pp. 1–9, 2010. View at: Publisher Site | Google Scholar
  29. Y. Zhu, M. R. Spitz, L. Lei, G. B. Mills, and X. Wu, “A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility,” Cancer Research, vol. 61, no. 21, pp. 7825–7829, 2001. View at: Google Scholar
  30. L. Joos, J. Q. He, M. B. Shepherdson et al., “The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function,” Human Molecular Genetics, vol. 11, no. 5, pp. 569–576, 2002. View at: Google Scholar
  31. F. Sanger, S. Nicklen, and A. R. Coulson, “DNA sequencing with chain-terminating inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 12, pp. 5463–5467, 1977. View at: Google Scholar
  32. R. Marttila, R. Haataja, M. Rämet, J. Löfgren, and M. Hallman, “Surfactant protein B polymorphism and respiratory distress syndrome in premature twins,” Human Genetics, vol. 112, no. 1, pp. 18–23, 2003. View at: Publisher Site | Google Scholar
  33. L. van Sonderen, E. F. W. Halsema, E. J. H. Spiering, and J. G. Koppe, “Genetic influences in respiratory distress syndrome: a twin study,” Seminars in Perinatology, vol. 26, no. 6, pp. 447–449, 2002. View at: Publisher Site | Google Scholar
  34. N. C. Myrianthopoulos, J. A. Churchill, and A. J. Baszynski, “Respiratory distress syndrome in twins,” Acta Geneticae Medicae et Gemellologiae, vol. 20, no. 2, pp. 199–204, 1971. View at: Google Scholar
  35. R. Marttila, J. Kaprio, and M. Hallman, “Respiratory distress syndrome in twin infants compared with singletons,” The American Journal of Obstetrics and Gynecology, vol. 191, no. 1, pp. 271–276, 2004. View at: Publisher Site | Google Scholar
  36. M. Hallman and R. Haataja, “Genetic basis of respiratory distress syndrome,” Frontiers in Bioscience, vol. 12, no. 7, pp. 2670–2682, 2007. View at: Publisher Site | Google Scholar
  37. A. Hilgendorff, K. Heidinger, A. Pfeiffer et al., “Association of polymorphisms in the mannose-binding lectin gene and pulmonary morbidity in preterm infants,” Genes and Immunity, vol. 8, no. 8, pp. 671–677, 2007. View at: Publisher Site | Google Scholar
  38. S. N. J. Kazzi, U. O. Kim, M. W. Quasney, and I. Buhimschi, “Polymorphism of tumor necrosis factor-alpha and risk and severity of bronchopulmonary dysplasia among very low birth weight infants,” Pediatrics, vol. 114, no. 2, pp. e243–e248, 2004. View at: Google Scholar
  39. G. Rocha, E. Proença, A. Areias et al., “HLA and bronchopulmonary dysplasia susceptibility: a pilot study,” Disease Markers, vol. 31, no. 4, pp. 199–203, 2011. View at: Publisher Site | Google Scholar
  40. M. H. Manar, M. R. Brown, T. W. Gauthier, and L. A. S. Brown, “Association of glutathione-S-transferase-P1 (GST-P1) polymorphisms with bronchopulmonary dysplasia,” Journal of Perinatology, vol. 24, no. 1, pp. 30–35, 2004. View at: Publisher Site | Google Scholar
  41. C. Danan, P. Jarreau, M. Franco et al., “Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 283, no. 5, pp. L1086–L1093, 2002. View at: Google Scholar
  42. C. G. Schulz, G. Sawicki, R. P. Lemke, B. M. Roeten, R. Schulz, and P. Cheung, “MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates,” Pediatric Research, vol. 55, no. 5, pp. 794–801, 2004. View at: Publisher Site | Google Scholar
  43. W. A. Dik, A. H. L. C. van Kaam, T. Dekker et al., “Early increased levels of matrix metalloproteinase-9 in neonates recovering from respiratory distress syndrome,” Biology of the Neonate, vol. 89, no. 1, pp. 6–14, 2006. View at: Publisher Site | Google Scholar
  44. A. L. S. Tai, J. S. T. Sham, D. Xie et al., “Co-overexpression of fibroblast growth factor 3 and epidermal growth factor receptor is correlated with the development of nonsmall cell lung carcinoma,” Cancer, vol. 106, no. 1, pp. 146–155, 2006. View at: Publisher Site | Google Scholar
  45. B. Zhao, S. S. Chua, M. M. Burcin et al., “Phenotypic consequences of lung-specific inducible expression of FGF-3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5898–5903, 2001. View at: Publisher Site | Google Scholar
  46. A. Hajitou, E. N. Baramova, K. Bajou et al., “FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells,” Oncogene, vol. 17, no. 16, pp. 2059–2071, 1998. View at: Google Scholar
  47. M. S. Park, E. Rieger-Fackeldey, B. L. Schanbacher et al., “Altered expressions of fibroblast growth factor receptors and alveolarization in neonatal mice exposed to 85% oxygen,” Pediatric Research, vol. 62, no. 6, pp. 652–657, 2007. View at: Publisher Site | Google Scholar
  48. S. Srisuma, S. Bhattacharya, D. M. Simon et al., “Fibroblast growth factor receptors control epithelial-mesenchymal interactions necessary for alveolar elastogenesis,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 8, pp. 838–850, 2010. View at: Publisher Site | Google Scholar

Copyright © 2013 Milad Rezvani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1391 Views | 836 Downloads | 19 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder